Skip to content

Efficacy and safety of Penetrating canaloplasty combined with phaco-emulsification in the treatment to pseudoexfoliation glaucoma: A prospective, two-center, case series

Efficacy and safety of Penetrating canaloplasty combined with phaco-emulsification in the treatment to pseudoexfoliation glaucoma: A prospective, two-center, case series

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097451
Enrollment
Unknown
Registered
2025-02-19
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pseudoexfoliation glaucoma

Interventions

PCP group:PCP combined with phaco?emulsification

Sponsors

Eye hospital of wenzhou medical university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with secondary glaucoma diagnosed with pseudocapsular decortication syndrome; 2. Age>=18 years old and 21mmHg or the intraocular pressure level <=21mmHg but the patient cannot tolerate the drug; 4. The patient has different degrees of lens opacity; 5. Voluntarily participate in this clinical study and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1. Patients who need to undergo other surgeries that may affect the accuracy and reliability of intraocular pressure measurement; 2. Patients who are unable to perform phacoemulsification cataract aspiration due to corneal diseases; 3. Patients with a history of internal eye surgery in the previously enrolled eye; 4. Patients with poor ocular conjunctival conditions and may have the risk of long-term leakage of postoperative incision; 5. Patients with other types of glaucoma in the enrolled eye; 6. Pregnant and lactating women; 7. Those who are unable to cooperate with the examination, such as patients with mental illness; 8. Have participated in other clinical trials within 30 days before enrollment and may affect the evaluation of this clinical trial; 9. Other conditions that the investigator considers unsuitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
qualified success;Complete success rate;Complications of surgery;

Countries

China

Contacts

Public ContactYuanbo Liang

Eye hospital of Wenzhou medical university

yuanboliang@126.com+86 182 5774 8686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026